IART Stock Analysis: Buy, Sell, or Hold?
IART - Integra LifeSciences Holdings
$10.78
-0.38 (-3.41%)
▼
5d:
-3.14%
30d:
-10.24%
90d:
-10.24%
HOLD
MODERATE Confidence
Last Updated: February 3, 2026
Earnings: Feb 24, 2026
20d
Get Alerted When IART Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called IART this week
50% bullish • 1 bearish
50% bullish • 1 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: IART shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: IART shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$16.20
Based on 5.4% avg growth
INTRINSIC VALUE TODAY
$10.06
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 5.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: IART is currently trading at $10.78, which is considered oversold relative to its 30-day fair value range of $11.40 to $13.04. From a valuation perspective, the stock is trading at a discount (Forward PE: 4.6) compared to its historical average (5.3). Remarkably, the market is currently pricing in an annual earnings decline of 4.7% over the next few years. This pessimistic expectation contrasts with the company's recent 0.4% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, IART is in a downtrend. The price is currently testing key support at $10.65. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.4% recently.
Market Sentiment: IART has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $15.50 (+43.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, IART is in a downtrend. The price is currently testing key support at $10.65. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.4% recently.
Market Sentiment: IART has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $15.50 (+43.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$11.40 -
$13.04
Company Quality Score
49/100
(HOLD)
Options IV Signal
50th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
55.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 50th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.4%)
- BULLISH: Trading 43.8% below Wall St target ($15.50)
Fair Price Analysis
30-Day Fair Range
$11.40 -
$13.04
Current vs Fair Value
OVERSOLD
Expected Move (7 Days)
±$1.13
(10.5%)
Support & Resistance Levels
Support Level
$10.65
Resistance Level
$12.52
Current Trend
Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
4.59
Wall Street Target
$15.50
(+43.8%)
Revenue Growth (YoY)
5.6%
Earnings Growth (YoY)
0.4%
Profit Margin
-30.1%
Valuation Discount vs History
-4.7% cheaper
PE vs Historical
4.6 vs 5.3
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-4.7%
(market-implied from PE analysis)
1-Year Target
$10.27
(-5%)
2-Year Target
$9.79
(-9%)
3-Year Target
$9.33
(-13%)
3-Yr Target (if PE normalizes)
(PE: 5→5)
$10.78
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.3, Growth: 6.8%)
$63.94
(+493%)
Base:
(SPY PE: 4.6, Growth: 6.8%)
$13.15
(+22%)
Bear:
(PE: 3.9, Growth: 6.8%)
$11.18
(+4%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 4.6 to 5.3
Stabilization Target:
$12.46
(+15.6%)
PE Expansion Potential:
+15.6%
Last updated: February 03, 2026 4:34 PM ET
Data refreshes hourly during market hours. Next update: 5:34 PM
Data refreshes hourly during market hours. Next update: 5:34 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IART showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$124 | 60 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$424 | 67 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
26 analysts |
$85 | 57 HOLD |
|
ABT
Abbott Laboratories |
BUY
28 analysts |
$134 | 62 BUY |
|
PODD
Insulet Corporation |
STRONG BUY
23 analysts |
$370 | 54 HOLD |
